Article
Genome-wide association study to characterize serum bilirubin elevations in patients with HCV treated with GS-9256, an HCV NS3 serine protease inhibitor.
Antiviral therapy - 1 Jan 2014
Nelson David, Yoshida Eric M, Paulson Matthew S, Hengen Paul N, Ge Dongliang, Kanwar Bittoo, McNally John, Pang Phillip S, Subramanian G Mani, McHutchison John G, Urbanek Petr, Lawitz Eric, Urban Thomas J
Abstract excerpt
BACKGROUND: Protease inhibitors for the treatment of HCV can cause mild and reversible elevations of unconjugated bilirubin. We sought to characterize genetic determinants of bilirubin elevations using a genome-wide approach among patients with genotype 1 HCV who received combination therapy that...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.